Skip to main content
Premium Trial:

Request an Annual Quote

Indivumed, Ultivue Sign Deal to Integrate Cancer Tissue Analysis Technologies

NEW YORK — Indivumed and Ultivue said on Wednesday that they have agreed to combine certain of their technologies into an offering for personalized cancer drug development.

Under the terms of the deal, the companies will join Indivumed's collection of standardized tissue biospecimens and immunohistochemistry (IHC) expertise with Ultivue's InSituPlex platform for high-throughput multiplex immunofluorescence.

Additional terms were not disclosed.

"By bringing Ultivue's technology and expertise into our workflow, we're giving our customers access to the contextual profiling of key cellular phenotypes," Indivumed Founder and CEO Hartmut Juhl said in a statement. "The data that can now be extracted from these valuable assets in our repository can support the full characterization of samples for biomarker and target discovery, drug development, clinical trials, and individualized therapy research. It will complete our offer in combination with the existing broad menu of IHC assays and end-to-end service."

In April, Hamburg, Germany-based Indivumed signed an agreement to integrate its IndivuType multiomic cancer database with genome and transcriptome-level data collected for samples collected using Personalis' advanced cancer genomics technology. 

In July, Cambridge, Massachusetts-based Ultivue began collaborating with OracleBio on an end-to-end workflow for tissue-based biomarker analysis.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.